Botanix Pharmaceuticals Limited

BOT

AU000000BOT2

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:13 2024-06-28 EDT			5-day change	1st Jan Change
0.345 ^AUD	-5.48%		-4.17%	+81.58%

06-21	Botanix Pharmaceuticals to Raise AU$70 Million via Institutional Placement	MT
06-20	Botanix Pharmaceuticals Secures US FDA Approval for Topical Medication	MT

Botanix Pharmaceuticals Limited Appoints Daniel Sharp as Non-Executive Director

March 21, 2022 at 09:33 pm

Botanix Pharmaceuticals Limited announced the appointment of Daniel Sharp, to the Botanix Board of Directors as a Non-Executive Director. He is currently a Non-Executive Director of health informatics company Alcidion Group Ltd.

Latest news about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals to Raise AU$70 Million via Institutional Placement	06-20	MT
Botanix Pharmaceuticals Secures US FDA Approval for Topical Medication	06-19	MT
Botanix Pharmaceuticals Submits Last Label Materials for Sofdra FDA Approval	06-11	MT
Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target	05-21	MT
Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy	05-13	MT
Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index	03-17	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
US FDA Accepts Resubmission of Botanix Pharmaceuticals' Topical Medication	01-21	MT
Botanix Pharmaceuticals Completes US FDA Resubmission for Topical Medication; Shares Gain 3%	12-20	MT
Botanix Pharmaceuticals Completes Human Factors Validation Study for Topical Medication; Shares Rise 3%	12-13	MT
Botanix Pharmaceuticals Secures US FDA Feedback for Topical Medication	12-04	MT
Botanix Pharmaceuticals Limited Receives Feedback from FDA	12-03	CI
Botanix Pharmaceuticals Completes Nearly AU$14 Million Institutional Placement	12-01	MT
Botanix Pharmaceuticals to Raise AU$13.5 Million in Placement; Shares Fall 3%	11-26	MT
Botanix Pharmaceuticals Signs Telehealth Deal for Dermatological Product	23-10-23	MT
Botanix Pharmaceuticals Secures Conditional US FDA Clearance for Use of 'Sofra' Trade Name	23-10-16	MT
Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX Emerging Companies Index	23-09-18	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Botanix Pharmaceuticals Promotes COO to CEO	23-08-25	MT
Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer	23-08-24	CI
Botanix Pharmaceuticals Raises Nearly AU$13 Million Via Institutional Placement	23-07-21	MT
Botanix Pharmaceuticals Partner Secures Sublicense, Distribution Deal in Korea	23-06-05	MT
Botanix Pharmaceuticals Limited Announces Company Secretary Changes	23-04-16	CI
Botanix Pharmaceuticals Completes AU$10 Million Placement	23-04-13	MT
Botanix Pharmaceuticals to Raise AU$10 Million in Placement	23-04-05	MT

Chart Botanix Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.345 AUD

Average target price

0.55 AUD

Spread / Average Target

+59.42%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
BOTANIX PHARMACEUTICALS LIMITED	+81.58%	417M
MERCK KGAA	+7.39%	72.09B
KYOWA KIRIN CO. LTD.	+15.93%	9.05B
SK BIOPHARMACEUTICALS CO., LTD.	-22.81%	4.4B
YUHAN CORPORATION	+17.59%	4.39B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+25.93%	3.94B
INDIVIOR PLC	+4.64%	2.1B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.97B
BETTA PHARMACEUTICALS CO., LTD.	-36.86%	1.87B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals